法瓦瑞斯制药

US · PHVS #2729 按市值排名上市于 2021

27.74 -1.90 -6.41%

实时 - 追踪5344个代码 - 心跳于462秒前 · 2026-10-16 20:02

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量减少了2家。
机构持股总比例下降了0.2个百分点。

机构持股

机构持股比例: 97.45% -0.16pp
机构数量: 142 -2
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

VC/PE Fund44.81%

Hedge Fund29.89%

Mutual Fund21.44%

Individual/Insider2.11%

Public Company0.64%

Private Company0.55%

Other0.44%

主要股东截至 2026-06-30

FMR 9.35% · 6.57M 股

General Atlantic Service Company, L.P. 9.33% · 6.55M 股

Foresite Capital Management, LLC 7.75% · 5.44M 股

venBio LLC 6.61% · 4.64M 股

Viking Global Investors LP 5.20% · 3.65M 股

EQT Life Sciences 5.07% · 3.56M 股

Eqt Fund Management S.à R.L. 4.88% · 3.42M 股

Deerfield Management Company, L.P. 4.81% · 3.38M 股

Bain Capital Life Sciences Investors, LLC 3.81% · 2.68M 股

Wellington Management Group 3.41% · 2.39M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 1次买入 · 49次卖出

姓名	职务	持股比例
Berndt Axel Modig	Chief Executive Officer	1.11%
Hans J. G. C. Schikan	Independent Vice Chairperson	0.16%
David Nassif	Chief Financial Officer	0.16%
Anne Lesage	Chief Early Development Officer	0.14%
Annick Deschoolmeester	Chief Human Resources Officer	0.13%
Peng Lu	Chief Medical Officer	0.10%
David Meeker	Independent Non-Executive Chairperson	0.09%
Anna Nijdam	Head of Strategic Finance & Principal Accounting Officer	0.07%
Stefan Abele	Chief Technology Operations Officer	0.06%
Wim Souverijns	Chief Community Engagement & Commercial Officer	0.06%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-09-22	Viviane Monges	Non-Executive Director	Derivative Exercise and Sale	-11,969	$8.05–33.05
2026-09-21	Hans J. G. C. Schikan	Independent Vice Chairperson	Derivative Exercise and Sale	-800	$20.00–36.19
2026-09-21	Peng Lu	Chief Medical Officer	Derivative Exercise and Retained	+45,308	$2.59
2026-09-20	David Nassif	Chief Financial Officer	Other Disposition	-500	--
2026-09-20	David Nassif	Chief Financial Officer	Open Market Disposition	-6,000	$36.47
2026-09-16	Robert Glassman	Independent Non-Executive Director	Derivative Exercise and Sale	-14,493	$18.14–38.56
2026-09-16	Berndt Axel Modig	Chief Executive Officer	Other Disposition	-300,000	$35.00
2026-09-16	Hans J. G. C. Schikan	Independent Vice Chairperson	Private Disposition	-200,000	$35.00
2026-09-16	Elisabeth Bjork	Non-Executive Director	Derivative Exercise and Sale	-52,500	$14.39–37.89
2026-09-16	Anne Lesage	Chief Early Development Officer	Open Market Disposition	-20,000	$38.27
2026-09-16	Peng Lu	Chief Medical Officer	Derivative Exercise and Sale	-100,000	$2.59–35.00
2026-09-14	Robert Glassman	Independent Non-Executive Director	Derivative Exercise and Sale	-8,667	$22.31–38.27
2026-09-14	Wim Souverijns	Chief Community Engagement & Commercial Officer	Automatic Disposition	-6,090	$38.99
2026-09-14	Stefan Abele	Chief Technology Operations Officer	Open Market Disposition	-1,400	$39.24
2026-09-14	Stefan Abele	Chief Technology Operations Officer	Derivative Exercise and Sale	-45,000	$16.40–38.14
2026-09-13	Berndt Axel Modig	Chief Executive Officer	Automatic Disposition	-2,291	$39.40
2026-09-13	Wim Souverijns	Chief Community Engagement & Commercial Officer	Derivative Exercise and Sale	-20,000	$17.43–39.31
2026-09-13	Peng Lu	Chief Medical Officer	Sale to Issuer	-226	$37.51–38.02
2026-09-10	Peng Lu	Chief Medical Officer	Derivative Exercise and Sale	-15,000	$2.59–40.13
2026-09-09	Anne Lesage	Chief Early Development Officer	Derivative Exercise and Sale	-30,000	$8.05–38.30

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:31 · 仅供参考，不构成投资建议，也未考虑您的具体情况。